Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 13 April, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 524394 | NSE: VIMTALABS

Vimta Labs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 12, 2025, 12:06 am

Market Cap 2,042 Cr.
Current Price 917
High / Low 1,183/420
Stock P/E34.9
Book Value 152
Dividend Yield0.22 %
ROCE16.8 %
ROE12.9 %
Face Value 2.00
PEG Ratio1.55

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vimta Labs Ltd

Competitors of Vimta Labs Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Choksi Laboratories Ltd 71.4 Cr. 102 142/51.055.3 33.00.00 %8.87 %5.12 % 10.0
Vimta Labs Ltd 2,042 Cr. 917 1,183/42034.9 1520.22 %16.8 %12.9 % 2.00
Industry Average2,042.00 Cr509.5045.1092.500.11%12.84%9.01%6.00

All Competitor Stocks of Vimta Labs Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 67747979768182647378738389
Expenses 46515554555758485055485456
Operating Profit 20232425212424172324252932
OPM % 31%31%30%32%27%29%29%26%31%30%34%35%37%
Other Income 10111110-10-1-15
Interest 0111100111001
Depreciation 67788889888810
Profit before tax 1516171814161681316161927
Tax % 25%27%27%26%27%23%25%25%25%24%26%24%23%
Net Profit 121212131012126912121521
EPS in Rs 5.235.375.445.914.505.545.252.674.275.325.256.589.46

Last Updated: February 28, 2025, 4:16 pm

Below is a detailed analysis of the quarterly data for Vimta Labs Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is 89.00 Cr.. The value appears strong and on an upward trend. It has increased from 83.00 Cr. (Sep 2024) to 89.00 Cr., marking an increase of 6.00 Cr..
  • For Expenses, as of Dec 2024, the value is 56.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 54.00 Cr. (Sep 2024) to 56.00 Cr., marking an increase of 2.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Sep 2024) to 32.00 Cr., marking an increase of 3.00 Cr..
  • For OPM %, as of Dec 2024, the value is 37.00%. The value appears strong and on an upward trend. It has increased from 35.00% (Sep 2024) to 37.00%, marking an increase of 2.00%.
  • For Other Income, as of Dec 2024, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Sep 2024) to 5.00 Cr., marking an increase of 6.00 Cr..
  • For Interest, as of Dec 2024, the value is 1.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
  • For Depreciation, as of Dec 2024, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Sep 2024) to 10.00 Cr., marking an increase of 2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Sep 2024) to 27.00 Cr., marking an increase of 8.00 Cr..
  • For Tax %, as of Dec 2024, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.00% (Sep 2024) to 23.00%, marking a decrease of 1.00%.
  • For Net Profit, as of Dec 2024, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Sep 2024) to 21.00 Cr., marking an increase of 6.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 9.46. The value appears strong and on an upward trend. It has increased from 6.58 (Sep 2024) to 9.46, marking an increase of 2.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:25 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 109127116138154183213181209276315313323
Expenses 8810199119127138155151156196222229213
Operating Profit 212617192745583053809484110
OPM % 19%20%15%14%18%25%27%17%25%29%30%27%34%
Other Income 1311112310344
Interest 3211255422322
Depreciation 1591110101620212323313434
Profit before tax 4187817263582855645278
Tax % 4%25%24%23%36%36%28%17%25%26%26%25%
Net Profit 4135611162572141473959
EPS in Rs 1.905.992.292.914.797.4311.453.139.6218.5721.3717.5126.61
Dividend Payout % 32%33%44%34%0%27%17%0%21%11%9%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)225.00%-61.54%20.00%83.33%45.45%56.25%-72.00%200.00%95.24%14.63%-17.02%
Change in YoY Net Profit Growth (%)0.00%-286.54%81.54%63.33%-37.88%10.80%-128.25%272.00%-104.76%-80.60%-31.66%

Vimta Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:8%
3 Years:14%
TTM:8%
Compounded Profit Growth
10 Years:11%
5 Years:9%
3 Years:22%
TTM:35%
Stock Price CAGR
10 Years:27%
5 Years:62%
3 Years:30%
1 Year:75%
Return on Equity
10 Years:12%
5 Years:14%
3 Years:17%
Last Year:13%

Last Updated: Unknown

Balance Sheet

Last Updated: January 13, 2025, 2:33 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 4444444444444
Reserves 108116118122132148167169190229276312334
Borrowings 127426444026323019151912
Other Liabilities 21222123424040394954656185
Total Liabilities 145149146176222232237245273306360396435
Fixed Assets 9390888888140135131128162168163175
CWIP 020653042170125975
Investments 0000000666666
Other Assets 51575882809299105122138174168179
Total Assets 145149146176222232237245273306360396435

Below is a detailed analysis of the balance sheet data for Vimta Labs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹334.00 Cr.. The value appears strong and on an upward trend. It has increased from 312.00 Cr. (Mar 2024) to ₹334.00 Cr., marking an increase of 22.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹12.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 19.00 Cr. (Mar 2024) to ₹12.00 Cr., marking a decrease of 7.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹85.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.00 Cr. (Mar 2024) to ₹85.00 Cr., marking an increase of 24.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹435.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 396.00 Cr. (Mar 2024) to ₹435.00 Cr., marking an increase of 39.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹175.00 Cr.. The value appears strong and on an upward trend. It has increased from 163.00 Cr. (Mar 2024) to ₹175.00 Cr., marking an increase of 12.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹75.00 Cr.. The value appears strong and on an upward trend. It has increased from 59.00 Cr. (Mar 2024) to ₹75.00 Cr., marking an increase of 16.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹179.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2024) to ₹179.00 Cr., marking an increase of 11.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹435.00 Cr.. The value appears strong and on an upward trend. It has increased from 396.00 Cr. (Mar 2024) to ₹435.00 Cr., marking an increase of 39.00 Cr..

Notably, the Reserves (334.00 Cr.) exceed the Borrowings (12.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow9.0019.0013.00-7.00-17.005.0032.00-2.0023.0061.0079.0065.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days87818210010111110011712810293101
Inventory Days165175158213183209199191140115187185
Days Payable1478766771841481151141398111961
Cash Conversion Cycle105169174236100172184194128136160224
Working Capital Days88841201266888871001169684102
ROCE %6%16%6%7%11%17%21%6%14%24%24%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters37.46%37.46%37.46%37.26%37.25%37.23%37.00%36.98%36.92%36.89%36.89%36.76%
FIIs0.36%0.35%0.49%2.28%2.25%2.72%2.74%2.88%5.13%5.16%3.31%3.81%
DIIs1.96%2.01%2.04%2.13%2.14%2.14%1.50%1.49%1.50%1.49%0.00%1.15%
Public60.22%60.18%60.02%58.35%58.37%57.92%58.75%58.65%56.45%56.45%59.80%58.28%
No. of Shareholders18,33218,10618,28318,91617,16217,43918,42919,95718,55019,05420,11421,156

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund330,1520.114.99N/AN/AN/A
Motilal Oswal S&P BSE Healthcare ETF780.040N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 18.5121.7718.709.683.10
Diluted EPS (Rs.) 18.2421.3518.329.683.10
Cash EPS (Rs.) 33.9235.6529.2420.1212.56
Book Value[Excl.RevalReserv]/Share (Rs.) 144.20127.33105.8387.9278.19
Book Value[Incl.RevalReserv]/Share (Rs.) 144.20127.33105.8387.9278.19
Revenue From Operations / Share (Rs.) 143.55143.78125.8695.2981.73
PBDIT / Share (Rs.) 40.9644.4436.9724.3314.91
PBIT / Share (Rs.) 25.5330.5726.4213.895.44
PBT / Share (Rs.) 24.5729.3725.1912.913.74
Net Profit / Share (Rs.) 18.5021.7718.699.683.10
NP After MI And SOA / Share (Rs.) 18.5021.7718.699.683.10
PBDIT Margin (%) 28.5230.9129.3725.5218.24
PBIT Margin (%) 17.7821.2520.9814.576.65
PBT Margin (%) 17.1120.4220.0113.544.57
Net Profit Margin (%) 12.8815.1314.8510.163.78
NP After MI And SOA Margin (%) 12.8815.1314.8510.163.78
Return on Networth / Equity (%) 12.8217.0917.6611.013.95
Return on Capital Employeed (%) 16.3622.1722.5113.926.39
Return On Assets (%) 10.2513.2913.457.802.78
Long Term Debt / Equity (X) 0.020.030.050.070.03
Total Debt / Equity (X) 0.060.050.080.110.13
Asset Turnover Ratio (%) 0.830.950.950.810.00
Current Ratio (X) 2.912.862.602.051.67
Quick Ratio (X) 2.462.462.241.781.37
Dividend Payout Ratio (NP) (%) 10.799.1710.690.0064.60
Dividend Payout Ratio (CP) (%) 5.885.606.830.0015.91
Earning Retention Ratio (%) 89.2190.8389.310.0035.40
Cash Earning Retention Ratio (%) 94.1294.4093.170.0084.09
Interest Coverage Ratio (X) 42.7937.1954.5624.818.76
Interest Coverage Ratio (Post Tax) (X) 20.3319.2129.4110.872.82
Enterprise Value (Cr.) 979.08670.65704.61372.30147.42
EV / Net Operating Revenue (X) 3.082.112.531.770.81
EV / EBITDA (X) 10.786.828.626.924.47
MarketCap / Net Operating Revenue (X) 3.102.192.501.690.72
Retention Ratios (%) 89.2090.8289.300.0035.39
Price / BV (X) 3.082.472.981.830.75
Price / Net Operating Revenue (X) 3.102.192.501.690.72
EarningsYield 0.040.060.050.060.05

After reviewing the key financial ratios for Vimta Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 18.51. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.51, marking a decrease of 3.26.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 18.24. This value is within the healthy range. It has decreased from 21.35 (Mar 23) to 18.24, marking a decrease of 3.11.
  • For Cash EPS (Rs.), as of Mar 24, the value is 33.92. This value is within the healthy range. It has decreased from 35.65 (Mar 23) to 33.92, marking a decrease of 1.73.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.55. It has decreased from 143.78 (Mar 23) to 143.55, marking a decrease of 0.23.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 40.96. This value is within the healthy range. It has decreased from 44.44 (Mar 23) to 40.96, marking a decrease of 3.48.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 30.57 (Mar 23) to 25.53, marking a decrease of 5.04.
  • For PBT / Share (Rs.), as of Mar 24, the value is 24.57. This value is within the healthy range. It has decreased from 29.37 (Mar 23) to 24.57, marking a decrease of 4.80.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
  • For PBDIT Margin (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has decreased from 30.91 (Mar 23) to 28.52, marking a decrease of 2.39.
  • For PBIT Margin (%), as of Mar 24, the value is 17.78. This value is within the healthy range. It has decreased from 21.25 (Mar 23) to 17.78, marking a decrease of 3.47.
  • For PBT Margin (%), as of Mar 24, the value is 17.11. This value is within the healthy range. It has decreased from 20.42 (Mar 23) to 17.11, marking a decrease of 3.31.
  • For Net Profit Margin (%), as of Mar 24, the value is 12.88. This value exceeds the healthy maximum of 10. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.88. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 12.82. This value is below the healthy minimum of 15. It has decreased from 17.09 (Mar 23) to 12.82, marking a decrease of 4.27.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 16.36. This value is within the healthy range. It has decreased from 22.17 (Mar 23) to 16.36, marking a decrease of 5.81.
  • For Return On Assets (%), as of Mar 24, the value is 10.25. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 10.25, marking a decrease of 3.04.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.83. It has decreased from 0.95 (Mar 23) to 0.83, marking a decrease of 0.12.
  • For Current Ratio (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.86 (Mar 23) to 2.91, marking an increase of 0.05.
  • For Quick Ratio (X), as of Mar 24, the value is 2.46. This value exceeds the healthy maximum of 2. There is no change compared to the previous period (Mar 23) which recorded 2.46.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.79. This value is below the healthy minimum of 20. It has increased from 9.17 (Mar 23) to 10.79, marking an increase of 1.62.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.88. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 23) to 5.88, marking an increase of 0.28.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 89.21. This value exceeds the healthy maximum of 70. It has decreased from 90.83 (Mar 23) to 89.21, marking a decrease of 1.62.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.12. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 23) to 94.12, marking a decrease of 0.28.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 37.19 (Mar 23) to 42.79, marking an increase of 5.60.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 19.21 (Mar 23) to 20.33, marking an increase of 1.12.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 979.08. It has increased from 670.65 (Mar 23) to 979.08, marking an increase of 308.43.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.11 (Mar 23) to 3.08, marking an increase of 0.97.
  • For EV / EBITDA (X), as of Mar 24, the value is 10.78. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.78, marking an increase of 3.96.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
  • For Retention Ratios (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 23) to 89.20, marking a decrease of 1.62.
  • For Price / BV (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.08, marking an increase of 0.61.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
  • For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Vimta Labs Ltd as of April 13, 2025 is: 548.66

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 13, 2025, Vimta Labs Ltd is Overvalued by 40.17% compared to the current share price 917.00

Intrinsic Value of Vimta Labs Ltd as of April 13, 2025 is: 672.48

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 13, 2025, Vimta Labs Ltd is Overvalued by 26.67% compared to the current share price 917.00

Last 5 Year EPS CAGR: 22.57%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (186.23 cr) compared to borrowings (22.00 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (204.38 cr) and profit (30.77 cr) over the years.
  1. The stock has a low average ROCE of 14.08%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 96.58, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 165.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vimta Labs Ltd:
    1. Net Profit Margin: 12.88%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 16.36% (Industry Average ROCE: 12.84%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 12.82% (Industry Average ROE: 9.01%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 20.33
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.46
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 34.9 (Industry average Stock P/E: 45.1)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.06
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Vimta Labs Ltd. is a Public Limited Listed company incorporated on 16/11/1990 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24110TG1990PLC011977 and registration number is 011977. Currently company belongs to the Industry of Medical Research Services. Company's Total Operating Revenue is Rs. 312.89 Cr. and Equity Capital is Rs. 4.43 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Medical Research ServicesPlot Nos. 141/2 & 142, IDA Phase II, Hyderabad Telangana 500051shares@vimta.com
http://www.vimta.com
Management
NamePosition Held
Dr. Sivalinga Prasad VasireddiExecutive Chairman
Ms. Harita VasireddiManaging Director
Mr. Harriman VungalExecutive Director - Operations
Mr. Satya Sreenivas NeerukondaExecutive Director
Dr. Yadagiri R PendriIndependent Director
Ms. Prameela Rani YalamanchiliIndependent Director
Mr. Sanjay DaveIndependent Director
Mr. Purnachandra Rao GuttaIndependent Director

FAQ

What is the intrinsic value of Vimta Labs Ltd?

Vimta Labs Ltd's intrinsic value (as of 13 April 2025) is ₹548.66 — 40.17% lower the current market price of 917.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,042 Cr. market cap, FY2025-2026 high/low of ₹1,183/420, reserves of 334 Cr, and liabilities of 435 Cr.

What is the Market Cap of Vimta Labs Ltd?

The Market Cap of Vimta Labs Ltd is 2,042 Cr..

What is the current Stock Price of Vimta Labs Ltd as on 13 April 2025?

The current stock price of Vimta Labs Ltd as on 13 April 2025 is 917.

What is the High / Low of Vimta Labs Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Vimta Labs Ltd stocks is ₹1,183/420.

What is the Stock P/E of Vimta Labs Ltd?

The Stock P/E of Vimta Labs Ltd is 34.9.

What is the Book Value of Vimta Labs Ltd?

The Book Value of Vimta Labs Ltd is 152.

What is the Dividend Yield of Vimta Labs Ltd?

The Dividend Yield of Vimta Labs Ltd is 0.22 %.

What is the ROCE of Vimta Labs Ltd?

The ROCE of Vimta Labs Ltd is 16.8 %.

What is the ROE of Vimta Labs Ltd?

The ROE of Vimta Labs Ltd is 12.9 %.

What is the Face Value of Vimta Labs Ltd?

The Face Value of Vimta Labs Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vimta Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE